MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Epithelioid

Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.

18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.

Interactive Cardiovascular and Thoracic Surgery 2020 January 31 [Link] Lococo F, Rena O, Torricelli F, Filice A, Rapicetta C, Boldorini R, Paci M, Versari A Abstract Although 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scan has been generally validated in the staging of malignant pleural mesothelioma (MPM), its diagnostic and prognostic performances are not clearly established. […]

Comments Off on 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.

Well-Differentiated Papillary Mesothelioma with Omental Calcifications: A Case Report and Review of the Literature.

The American Journal of Case Reports 2020 January 13 [Link] Erem AS, Allamaneni SS, Braverman TS Abstract BACKGROUND Omental calcifications of the peritoneum are typically small and asymptomatic. However, larger psammomatous bodies that cause symptoms such as abdominal pain and bloating are often associated with tumors such as primary serous papillary carcinoma, mesothelioma, or metastatic […]

Comments Off on Well-Differentiated Papillary Mesothelioma with Omental Calcifications: A Case Report and Review of the Literature.

Combined MEK and PI3K/p110b inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features.

Cancer Research 2020 January 7 [Link] Marqués M, Tranchant R, Risa-Ebrí B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, Del Pozo N, Martínez de Villarreal J, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX Abstract Among malignant mesotheliomas (MM) the sarcomatoid subtype is associated […]

Comments Off on Combined MEK and PI3K/p110b inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features.

Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion.

BMJ Case Reports 2020 January 2 [Link] Hinkamp CA, Dalal SN, Butt Y, Cabo Chan Abstract Malignant mesothelioma is an uncommon form of neoplastic transformation of the mesothelial cells that line the serosal surfaces of the body. It most commonly affects the pleura and is often associated with pleural effusions and pleural-based masses. The annual […]

Comments Off on Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion.

A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations.

Oncology Letters 2020 January [Link] Alì G, Bruno R, Poma AM, Proietti A, Ricci S, Chella A, Melfi F, Ambrogi MC, Lucchi M, Fontanini G Abstract The demonstration of tissue invasion by histology is an essential criterion for the differential diagnosis of benign and malignant mesothelial proliferations. When tissue invasion cannot be identified, the use […]

Comments Off on A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations.

Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases.

The American Journal of Surgical Pathology 2019 December 23 [Link] Pavlisko EN, Liu B, Green C, Sporn TA, Roggli VL Abstract We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% pleural MM and 22% peritoneal MM. The […]

Comments Off on Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases.

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

Respiratory Medicine Case Reports 2019 November 21 [Link] Dalgleish AG, McLean E, Patel N, Rahman N Abstract A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own […]

Comments Off on Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.

Lung Cancer 2019 November 18 [Link] Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with dismal prognosis but variable course of disease. To support diagnosis and to risk stratify patients, more reliable biomarkers are warranted. Emerging evidence underlines a […]

Comments Off on Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.

Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.

International Journal of Molecular Science 2019 November 19 [Link] Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, Pilotti S, Baratti D, Guaglio M, Deraco M, Kusamura S, Perrone F Abstract Background-There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients […]

Comments Off on Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.

The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype.

Molecular Cancer Research 2019 Novemver 15 [Link] Eckert RL, Kandasamy S, Adhikary G, Rorke EA, Friedberg JS, Mickle MB, Alexander HR Abstract Mesothelioma is an aggressive cancer that has a poor prognosis. Tumors develop in the mesothelial lining of the pleural and peritoneal cavities in response to asbestos exposure. Surgical debulking followed by chemotherapy is […]

Comments Off on The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype.